ID   FM95
AC   CVCL_C618
SY   FM-95
DR   cancercelllines; CVCL_C618
DR   Cosmic; 851403
DR   Cosmic; 1047685
DR   Cosmic; 2163784
DR   ECACC; 13012425
DR   ESTDAB; ESTDAB-034
DR   GEO; GSM156012
DR   IARC_TP53; 26111
DR   Progenetix; CVCL_C618
DR   Wikidata; Q54835077
RX   PubMed=9288767;
RX   PubMed=15592718;
RX   PubMed=17260012;
RX   PubMed=23851445;
CC   HLA typing: A*03:01,33:01; B*07:02,51:01:01; C*07:02,14:02:01; DPB1*04:01,10:01; DQB1*03:01:01,05:03:01; DRB1*12:01,14:01 (PubMed=15592718).
CC   Sequence variation: Mutation; HGNC; HGNC:1097; BRAF; Simple; p.Leu597Ser (c.1789_1790delCTinsTC); ClinVar=VCV000375942; Zygosity=Unspecified (PubMed=17260012; PubMed=23851445).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Arg181Cys (c.541C>T); ClinVar=VCV000142624; Zygosity=Unspecified (PubMed=17260012; PubMed=23851445).
CC   Omics: Variations; Array-based CGH.
CC   Discontinued: ESTDAB; ESTDAB-034; probable.
CC   Derived from site: Metastatic; Skin; UBERON=UBERON_0002097.
ST   Source(s): ECACC=13012425
ST   Amelogenin: X,Y
ST   CSF1PO: 10,11
ST   D13S317: 9,10
ST   D16S539: 9,13
ST   D5S818: 12,13
ST   D7S820: 8,11
ST   TH01: 9.3
ST   TPOX: 8
ST   vWA: 15,18
DI   NCIt; C3510; Cutaneous melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   Age unspecified
CA   Cancer cell line
DT   Created: 22-10-12; Last updated: 10-04-25; Version: 21
//
RX   PubMed=9288767;
RA   Guldberg P., thor Straten P., Birck A., Ahrenkiel V., Kirkin A.F.,
RA   Zeuthen J.;
RT   "Disruption of the MMAC1/PTEN gene by deletion or mutation is a
RT   frequent event in malignant melanoma.";
RL   Cancer Res. 57:3660-3663(1997).
//
RX   PubMed=15592718; DOI=10.1007/s00262-004-0561-5; PMCID=PMC11032966;
RA   Rodriguez T., Mendez R., Roberts C.H., Ruiz-Cabello Osuna F., Dodi I.A.,
RA   Lopez-Nevot M.A., Paco L., Maleno I., Marsh S.G.E., Pawelec G.,
RA   Garrido F.;
RT   "High frequency of homozygosity of the HLA region in melanoma cell
RT   lines reveals a pattern compatible with extensive loss of
RT   heterozygosity.";
RL   Cancer Immunol. Immunother. 54:141-148(2005).
//
RX   PubMed=17260012; DOI=10.1038/sj.onc.1210252;
RA   Jonsson G., Dahl C., Staaf J., Sandberg T., Bendahl P.-O., Ringner M.,
RA   Guldberg P., Borg A.;
RT   "Genomic profiling of malignant melanoma using tiling-resolution
RT   arrayCGH.";
RL   Oncogene 26:4738-4748(2007).
//
RX   PubMed=23851445; DOI=10.1158/1541-7786.MCR-13-0006;
RA   Dahl C., Christensen C., Jonsson G., Lorentzen A., Skjodt M.L.,
RA   Borg A., Pawelec G., Guldberg P.;
RT   "Mutual exclusivity analysis of genetic and epigenetic drivers in
RT   melanoma identifies a link between p14 ARF and RARbeta signaling.";
RL   Mol. Cancer Res. 11:1166-1178(2013).
//